Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2011 Dec 20;29(36):4845-6.
doi: 10.1200/JCO.2011.38.6094. Epub 2011 Oct 31.

Idiotype vaccination as consolidation therapy: time for integration into standard of care for follicular lymphoma?

Stephen J Schuster, Sattva S Neelapu, Carlos F Santos, Mihaela A Popa-McKiver, Amy M McCord, Larry W Kwak
Comment

Idiotype vaccination as consolidation therapy: time for integration into standard of care for follicular lymphoma?

Stephen J Schuster et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Ansell SM, Suman VJ. Identifying patients with follicular lymphoma who are likely to benefit from an idiotype vaccine. J Clin Oncol. 2011;29:2748–2749. - PubMed
    1. Schuster SJ, Neelapu SS, Gause BL, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol. 2011;29:2787–2794. - PMC - PubMed
    1. National Comprehensive Cancer Network (NCCN) NCCN clinical practice guidelines in oncology (NCCN Guidelines): Non-Hodgin's lymphomas. Version 2.2011. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
    1. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42–51. - PubMed
    1. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final Results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). 51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, LA. abstr 405.

MeSH terms